应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
02268 药明合联
午间休市 07-30 11:59:59
61.700
-0.050
-0.08%
最高
63.150
最低
59.600
成交量
502.31万
今开
61.400
昨收
61.750
日振幅
5.75%
总市值
742.25亿
流通市值
742.25亿
总股本
12.03亿
成交额
3.10亿
换手率
0.42%
流通股本
12.03亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
药明合联07月29日主力净流入403.0万元 散户资金抛售
市场透视 · 07-29 08:15
药明合联07月29日主力净流入403.0万元 散户资金抛售
大行评级丨麦格理:药明康德中绩胜预期 重申目标价116港元
格隆汇 · 07-29 05:19
大行评级丨麦格理:药明康德中绩胜预期 重申目标价116港元
大行评级|瑞银:药明康德中期业绩符合预期 予其“买入”评级
格隆汇 · 07-29 02:47
大行评级|瑞银:药明康德中期业绩符合预期 予其“买入”评级
药明合联盘中异动 急速拉升5.07%报59.100港元
市场透视 · 07-28 06:43
药明合联盘中异动 急速拉升5.07%报59.100港元
【医药】集采“反内卷”,关注受益标的——医药生物行业周报
渤海证券研究 · 07-28 01:13
【医药】集采“反内卷”,关注受益标的——医药生物行业周报
药明合联07月24日获主力加仓3222.9万元
市场透视 · 07-24
药明合联07月24日获主力加仓3222.9万元
港股异动 | 药明合联(02268.HK)再涨超3% 公司上半年业绩预告胜过市场预期 无锡新投产能迅速爬坡
智通财经 · 07-24
港股异动 | 药明合联(02268.HK)再涨超3% 公司上半年业绩预告胜过市场预期 无锡新投产能迅速爬坡
花旗:药明合联(02268)上半年净利胜预期 重申“买入”评级
智通财经 · 07-24
花旗:药明合联(02268)上半年净利胜预期 重申“买入”评级
药明合联供需两旺驱动1H25业绩超预期
交银国际 · 07-24
药明合联供需两旺驱动1H25业绩超预期
药明合联07月23日主力净流入3303.3万元 散户资金抛售
市场透视 · 07-23
药明合联07月23日主力净流入3303.3万元 散户资金抛售
CXO 复苏?药明合联上半年收入大涨 60%
Insight数据库 · 07-23
CXO 复苏?药明合联上半年收入大涨 60%
港股异动丨药明合联涨超12%创新高,预期上半年净利同比增长超50%
老虎资讯综合 · 07-23
港股异动丨药明合联涨超12%创新高,预期上半年净利同比增长超50%
港股异动 | 药明合联(02268)高开逾9% 预计上半年收入同比增超六成 净利润同比增超50%
智通财经 · 07-23
港股异动 | 药明合联(02268)高开逾9% 预计上半年收入同比增超六成 净利润同比增超50%
药明合联盈喜:预计中期经调整净利润增长超过67%
格隆汇资讯 · 07-22
药明合联盈喜:预计中期经调整净利润增长超过67%
药明合联07月21日遭主力抛售401.1万元
市场透视 · 07-21
药明合联07月21日遭主力抛售401.1万元
药明合联07月18日遭主力抛售2956.8万元
市场透视 · 07-18
药明合联07月18日遭主力抛售2956.8万元
药明合联盘中异动 早盘急速拉升5.12%报51.300港元
市场透视 · 07-17
药明合联盘中异动 早盘急速拉升5.12%报51.300港元
每日卖空追踪 | 药明合联 07月16日卖空量成交10.25万股,卖空比例为2.66%
市场透视 · 07-16
每日卖空追踪 | 药明合联 07月16日卖空量成交10.25万股,卖空比例为2.66%
医药生物行业周报:艾伯维19.25亿美元引进CD3/BCMA/CD38三抗,关注TCE多抗的投资机遇
信达证券 · 07-15
医药生物行业周报:艾伯维19.25亿美元引进CD3/BCMA/CD38三抗,关注TCE多抗的投资机遇
每日卖空追踪 | 药明合联 07月15日卖空量成交17.9万股,卖空比例为2.99%
市场透视 · 07-15
每日卖空追踪 | 药明合联 07月15日卖空量成交17.9万股,卖空比例为2.99%
加载更多
公司概况
公司名称:
药明合联
所属市场:
SEHK
上市日期:
--
主营业务:
药明合联生物技术有限公司是一家主要从事提供提供抗体偶联药物(ADC)及其他生物偶联药物的全面合同研究、开发及制造组织(CRDMO)服务的投资控股公司。该公司的服务包括生物偶联药物、单克隆抗体中间体及生物偶联药物相关连接子及有效载荷的发现、工艺开发及优良生产质量管理规范(GMP)生产。该公司透过按有偿服务(FFS)基准的合约和按全时当量(FTE)基准的合约向客户提供CRDMO服务。该公司主要在国内市场、北美、欧洲和世界其他地区市场开展业务。
发行价格:
--
{"stockData":{"symbol":"02268","market":"HK","secType":"STK","nameCN":"药明合联","latestPrice":61.7,"timestamp":1753847999898,"preClose":61.75,"halted":0,"volume":5023149,"delay":0,"floatShares":1203000000,"shares":1203000000,"eps":0.9760137920715911,"marketStatus":"午间休市","change":-0.05,"latestTime":"07-30 11:59:59","open":61.4,"high":63.15,"low":59.6,"amount":310388476,"amplitude":0.05749,"askPrice":61.75,"askSize":13000,"bidPrice":61.65,"bidSize":2500,"shortable":3,"etf":0,"ttmEps":0.9076562578773845,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1753851600000},"marketStatusCode":3,"adr":0,"listingDate":1700150400000,"exchange":"SEHK","adjPreClose":61.75,"openAndCloseTimeList":[[1753839000000,1753848000000],[1753851600000,1753862400000]],"volumeRatio":1.258968,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02268","defaultTab":"news","newsList":[{"id":"2555039875","title":"药明合联07月29日主力净流入403.0万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2555039875","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555039875?lang=zh_cn&edition=full","pubTime":"2025-07-29 16:15","pubTimestamp":1753776949,"startTime":"0","endTime":"0","summary":"07月29日, 药明合联股价涨4.84%,报收61.75元,成交金额4.8亿元,换手率0.66%,振幅5.86%,量比1.00。药明合联今日主力资金净流入403.0万元,上一交易日主力净流出320.7万元。该股近5个交易日上涨25.51%,主力资金累计净流入6042.1万元;近20日主力资金累计净流入3387.3万元,其中净流入天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729165944a4695441&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729165944a4695441&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","02268","SG9999014674.SGD","LU2488822045.USD"],"gpt_icon":0},{"id":"2555084505","title":"大行评级丨麦格理:药明康德中绩胜预期 重申目标价116港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2555084505","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555084505?lang=zh_cn&edition=full","pubTime":"2025-07-29 13:19","pubTimestamp":1753766355,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU1997245094.SGD","LU2495084118.USD","LU1997245177.USD","LU1969619763.USD","BK0216","BK1576","LU2045819591.USD","LU0456842615.SGD","02268","LU0708995583.HKD","LU0320764599.SGD","LU2125910500.SGD","LU2328871848.SGD","LU0052750758.USD","LU1046422090.SGD","BK1141","BK1583","BK4590","LU2242644610.SGD","BK4144","GLP","LU2488822045.USD","603259","159201","02359","LU1997244956.HKD","SG9999014674.SGD"],"gpt_icon":0},{"id":"2555689086","title":"大行评级|瑞银:药明康德中期业绩符合预期 予其“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2555689086","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555689086?lang=zh_cn&edition=full","pubTime":"2025-07-29 10:47","pubTimestamp":1753757233,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1583","LU1969619763.USD","SG9999014674.SGD","BK0216","LU2328871848.SGD","LU1997245094.SGD","LU1046422090.SGD","BK1141","LU2242644610.SGD","LU2045819591.USD","LU0052750758.USD","LU2488822045.USD","LU1997244956.HKD","LU2495084118.USD","02359","02268","LU0320764599.SGD","LU2125910500.SGD","LU1997245177.USD","603259","LU0708995583.HKD","BK1576","LU0456842615.SGD"],"gpt_icon":0},{"id":"2554014725","title":"药明合联盘中异动 急速拉升5.07%报59.100港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2554014725","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554014725?lang=zh_cn&edition=full","pubTime":"2025-07-28 14:43","pubTimestamp":1753685036,"startTime":"0","endTime":"0","summary":"2025年07月28日下午盘14时43分,药明合联股票出现异动,股价快速上涨5.07%。截至发稿,该股报59.100港元/股,成交量460.052万股,换手率0.38%,振幅5.96%。资金方面,该股资金流入1.30016亿港元,流出9760.83万港元。机构评级方面,在所有10家参与评级的机构中,90%的券商给予买入建议,10%的券商给予持有建议,无券商给予卖出建议。药明合联股票所在的生物技术行业中,整体涨幅为1.77%。业绩预告公布当日,药明合联股价一度跳空大涨超过14%,创新高。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250728144357a6c55d1e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250728144357a6c55d1e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02268","BK1141","LU2488822045.USD","SG9999014674.SGD"],"gpt_icon":0},{"id":"2554744063","title":"【医药】集采“反内卷”,关注受益标的——医药生物行业周报","url":"https://stock-news.laohu8.com/highlight/detail?id=2554744063","media":"渤海证券研究","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554744063?lang=zh_cn&edition=full","pubTime":"2025-07-28 09:13","pubTimestamp":1753665229,"startTime":"0","endTime":"0","summary":"集采规则持续优化,建议关注受益于集采规则优化的制药和医疗器械板块。综上,我们维持行业“看好”评级。订阅者应当充分了解各类投资风险,根据自身情况自主做出投资决策并自行承担投资风险。如因侵权行为给渤海证券造成任何直接或间接损失,渤海证券保留追究一切法律责任的权利。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072809265194be4461&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072809265194be4461&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02269","WXIBF","BK4121","02268"],"gpt_icon":0},{"id":"2553720056","title":"药明合联07月24日获主力加仓3222.9万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2553720056","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553720056?lang=zh_cn&edition=full","pubTime":"2025-07-24 16:15","pubTimestamp":1753344951,"startTime":"0","endTime":"0","summary":"07月24日, 药明合联股价涨6.43%,报收57.10元,成交金额5.7亿元,换手率0.84%,振幅6.90%,量比1.40。药明合联今日主力资金净流入3222.9万元,上一交易日主力净流入3303.3万元。该股近5个交易日上涨13.63%,主力资金累计净流入1518.1万元;近20日主力资金累计净流入5245.0万元,其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724170102a460edf9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724170102a460edf9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","SG9999014674.SGD","02268","LU2488822045.USD"],"gpt_icon":0},{"id":"2553222749","title":"港股异动 | 药明合联(02268.HK)再涨超3% 公司上半年业绩预告胜过市场预期 无锡新投产能迅速爬坡","url":"https://stock-news.laohu8.com/highlight/detail?id=2553222749","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553222749?lang=zh_cn&edition=full","pubTime":"2025-07-24 10:01","pubTimestamp":1753322473,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2488822045.USD","02268","SG9999014674.SGD","BK1141"],"gpt_icon":0},{"id":"2553270221","title":"花旗:药明合联(02268)上半年净利胜预期 重申“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2553270221","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553270221?lang=zh_cn&edition=full","pubTime":"2025-07-24 09:13","pubTimestamp":1753319626,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,花旗发布研报称,药明合联(02268)发盈喜,按国际财务报告准则,预期上半年收入同比增长超过60%,经调整净利润(不含利息收入及开支)增长超过67%,净利润增长逾50%,表现好过市场预期上半年营收和净利分别同比增长52%和26%。营收则符合该行预期,净利较该行预测高出32%。报告指,药明合联管理层将强劲的增长归功于ADC产业的高客户需求、公司拥有高市占率的市场领导地位,以及生产设施利用率的提升。该行重申对药明合联“买入”评级,目标价46港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1321312.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02268"],"gpt_icon":0},{"id":"2553229799","title":"药明合联供需两旺驱动1H25业绩超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2553229799","media":"交银国际","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553229799?lang=zh_cn&edition=full","pubTime":"2025-07-24 08:15","pubTimestamp":1753316133,"startTime":"0","endTime":"0","summary":"随着ADC出海交易热潮持续拉动下游订单需求、无锡厂房更多新产线和新加坡厂房投入运营,我们预计2H25-2026年业绩维持高增长的能见度较强。公司将于8月18日公布1H25详细业绩,我们将持续关注,并基于1H25业绩对盈利预测及目标价进行动态调整。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724084047a4600106&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724084047a4600106&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","LU2488822045.USD","02268","SG9999014674.SGD"],"gpt_icon":0},{"id":"2553521318","title":"药明合联07月23日主力净流入3303.3万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2553521318","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553521318?lang=zh_cn&edition=full","pubTime":"2025-07-23 16:15","pubTimestamp":1753258539,"startTime":"0","endTime":"0","summary":"07月23日, 药明合联股价涨8.60%,报收53.65元,成交金额6.6亿元,换手率1.01%,振幅9.92%,量比2.21。药明合联今日主力资金净流入3303.3万元,上一交易日主力净流出1650.1万元。该股近5个交易日上涨9.32%,主力资金累计净流出4401.2万元;近20日主力资金累计净流入1545.4万元,其中净流入天数为8日。该股主力净额占比0.05%,港股市场排名177/2672。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723165750a6bcea61&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723165750a6bcea61&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02268","SG9999014674.SGD","LU2488822045.USD","BK1141"],"gpt_icon":0},{"id":"2553294937","title":"CXO 复苏?药明合联上半年收入大涨 60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2553294937","media":"Insight数据库","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553294937?lang=zh_cn&edition=full","pubTime":"2025-07-23 13:20","pubTimestamp":1753248024,"startTime":"0","endTime":"0","summary":"7 月 23 日,药明合联发布盈利预告,上半年收入增长超过 60%,经调整净利润增长超过 67%,净利润增长超过 50%。受此消息影响,药明合联盘中涨幅一度超过 12%。药明康德上半年预计营收 208 亿元,同比增长 20.6%,归母净利润约为 85.6 亿元,同比增长 101.9%。康龙化成预计上半年营收 63.33-65.01 亿,同比增长 13%-16%,扣非净利润 6.24-6.48 亿,同比增长 34%039%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723143205a45e1dbd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723143205a45e1dbd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02359","LU2488822045.USD","SG9999014674.SGD","BK1141","02268","603259"],"gpt_icon":0},{"id":"1184965243","title":"港股异动丨药明合联涨超12%创新高,预期上半年净利同比增长超50%","url":"https://stock-news.laohu8.com/highlight/detail?id=1184965243","media":"老虎资讯综合","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184965243?lang=zh_cn&edition=full","pubTime":"2025-07-23 09:58","pubTimestamp":1753235927,"startTime":"0","endTime":"0","summary":"7月23日,$药明合联(02268)$盘初拉升涨超12%,股价创上市新高。公司公告,集团预期2025年上半年收入同比增长超过60%,经调整净利润(不含利息收入及开支)同比增长超过67%,净利润同比增长超过50%。公司认为,有关预期增长主要归因于以下因素:抗体偶联药物(ADC)及更广泛$生物(000504)$偶联药物行业的下游需求持续旺盛;集团通过稳固的领先地位及竞争优势,获得生物偶联药物CRDMO的重要市场份额;及集团新投产线的产能迅速爬坡,生产设施持续保持高利用率及运营效率的持续提升。","market":"us","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"aafa41a61db4c8d521e55fc890d73ff0","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268","SG9999014674.SGD","LU2488822045.USD","BK4614","BK1141"],"gpt_icon":0},{"id":"2553262001","title":"港股异动 | 药明合联(02268)高开逾9% 预计上半年收入同比增超六成 净利润同比增超50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2553262001","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553262001?lang=zh_cn&edition=full","pubTime":"2025-07-23 09:23","pubTimestamp":1753233797,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,药明合联(02268)高开逾9%,截至发稿,涨9.11%,报53.9港元,成交额730.35万港元。消息面上,药明合联公布,预期2025年上半年收入同比增长超过60%,经调整净利润( 不含利息收入及开支)同比增长超过67%,净利润同比增长超过50%。公司认为,有关预期增长主要归因于抗体偶联药物(ADC)及更广泛生物偶联药物行业的下游需求持续旺盛;集团通过稳固的领先地位及竞争优势,获得生物偶联药物CRDMO的重要市场份额;集团新投产线的产能迅速爬坡,生产设施持续保持高利用率及运营效率的持续提升。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":"aafa41a61db4c8d521e55fc890d73ff0","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1320842.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02268"],"gpt_icon":0},{"id":"2553269443","title":"药明合联盈喜:预计中期经调整净利润增长超过67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2553269443","media":"格隆汇资讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553269443?lang=zh_cn&edition=full","pubTime":"2025-07-23 07:04","pubTimestamp":1753225481,"startTime":"0","endTime":"0","summary":"格隆汇7月23日丨药明合联(02268.HK)发布公告,截至2025年6月30日止六个月,预期集团录得较上年同期财务业绩:(1)收入增长超过60%;(2)经调整净利润(不含利息收入及开支)增长超过67%;及(3)净利润增长超过50%。公司认为,有关预期增长主要归因于以下因素:(1)抗体偶联药物(ADC)及更广泛生物偶联药物行业的下游需求持续旺盛;(2)集团通过稳固的领先地位及竞争优势,获得生物偶联药物CRDMO的重要市场份额;及(3)集团新投产线的产能迅速爬坡,生产设施持续保持高利用率及运营效率的持续提升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072307044597b14e21&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072307044597b14e21&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02268"],"gpt_icon":0},{"id":"2553475994","title":"药明合联07月21日遭主力抛售401.1万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2553475994","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553475994?lang=zh_cn&edition=full","pubTime":"2025-07-21 16:15","pubTimestamp":1753085749,"startTime":"0","endTime":"0","summary":"07月21日, 药明合联股价跌0.10%,报收49.45元,成交金额3.3亿元,换手率0.55%,振幅4.24%,量比1.02。药明合联今日主力资金净流出401.1万元,连续6日净流出,上一交易日主力净流出2956.8万元。该股近5个交易日上涨1.35%,主力资金累计净流出6281.5万元;近20日主力资金累计净流出622.7万元,其中净流出天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250721165824a6b78c01&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250721165824a6b78c01&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02268","LU2488822045.USD","BK1141","SG9999014674.SGD"],"gpt_icon":0},{"id":"2552449176","title":"药明合联07月18日遭主力抛售2956.8万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2552449176","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552449176?lang=zh_cn&edition=full","pubTime":"2025-07-18 16:15","pubTimestamp":1752826545,"startTime":"0","endTime":"0","summary":"07月18日, 药明合联股价跌1.49%,报收49.50元,成交金额1.8亿元,换手率0.30%,振幅3.78%,量比0.44。药明合联今日主力资金净流出2956.8万元,连续5日净流出,上一交易日主力净流出2696.4万元。近一年数据显示,该股主力连续5日净流出后,次日下跌概率为66.67%,平均跌幅为1.79%。该股近5个交易日上涨7.61%,主力资金累计净流出6609.9万元;近20日主力资金累计净流出426.7万元,其中净流出天数为13日。该股主力净额占比0.05%,港股市场排名2527/2671。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718172040a6b1c9e6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718172040a6b1c9e6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02268","BK1141","LU2488822045.USD","SG9999014674.SGD"],"gpt_icon":0},{"id":"2552510960","title":"药明合联盘中异动 早盘急速拉升5.12%报51.300港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2552510960","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552510960?lang=zh_cn&edition=full","pubTime":"2025-07-17 09:59","pubTimestamp":1752717597,"startTime":"0","endTime":"0","summary":"2025年07月17日早盘09时59分,药明合联股票出现异动,股价急速上涨5.12%。截至发稿,该股报51.300港元/股,成交量180.827万股,换手率0.15%,振幅5.74%。资金方面,该股资金流入4391.82万港元,流出2683.93万港元。药明合联股票所在的生物技术行业中,整体涨幅为5.06%。其相关个股中,三叶草生物-B、复旦张江、康方生物涨幅较大,振幅较大的相关个股有三叶草生物-B、复旦张江、歌礼制药-B,振幅分别为23.94%、15.32%、12.04%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717095957a6ae910a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717095957a6ae910a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02268","SG9999014674.SGD","BK1141","LU2488822045.USD"],"gpt_icon":0},{"id":"2552184127","title":"每日卖空追踪 | 药明合联 07月16日卖空量成交10.25万股,卖空比例为2.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2552184127","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552184127?lang=zh_cn&edition=full","pubTime":"2025-07-16 16:30","pubTimestamp":1752654632,"startTime":"0","endTime":"0","summary":"药明合联北京时间07月16日,涨0.1%,卖空量成交10.25万股%,较上一交易日减少67.2%更多个股卖空数据请看下面视窗:卖空数据是观测市场多空博弈的关键指标:短期可反映市场情绪,高卖空比例预示看空预期,但极端值可能触发轧空反弹;长期结合基本面恶化则预警下行风险。需注意其局限性:卖空行为包含对冲需求,未必单纯看空;机构可能通过衍生品做空未体现在数据中,且散户跟风易扭曲信号。股市有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716172619a6ad2117&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716172619a6ad2117&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02268","LU2488822045.USD","BK1141","SG9999014674.SGD"],"gpt_icon":0},{"id":"2551919964","title":"医药生物行业周报:艾伯维19.25亿美元引进CD3/BCMA/CD38三抗,关注TCE多抗的投资机遇","url":"https://stock-news.laohu8.com/highlight/detail?id=2551919964","media":"信达证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551919964?lang=zh_cn&edition=full","pubTime":"2025-07-16 00:06","pubTimestamp":1752595576,"startTime":"0","endTime":"0","summary":"本期内容提要:上周市场表现:上周医药生物板块收益率为2.82%,板块相对沪深300收益率为+1.56%,在31个一级子行业指数中涨跌幅排名第6。上周重点关注:2025年7月10日,艾伯维以19.25亿美元引进IGI Therapeutics CD3/BCMA/CD38三特异性抗体ISB2001,获得其在北美、欧洲、日本及大中华区的独家权益,这是继2024年艾伯维以10.55亿美元引进先声药业GPRC5D/BCMA/CD3三抗后,在血液瘤领域的又一次战略布局,建议关注TCE多抗的投资机遇,相关企业:百利天恒、汇宇制药、信达生物、先声药业等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071600063497a73ffa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071600063497a73ffa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02096","02269","02268","01801","603259"],"gpt_icon":0},{"id":"2551516988","title":"每日卖空追踪 | 药明合联 07月15日卖空量成交17.9万股,卖空比例为2.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2551516988","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551516988?lang=zh_cn&edition=full","pubTime":"2025-07-15 16:30","pubTimestamp":1752568227,"startTime":"0","endTime":"0","summary":"药明合联北京时间07月15日,涨1.25%,卖空量成交17.9万股%,较上一交易日减少70.78%更多个股卖空数据请看下面视窗:卖空数据是观测市场多空博弈的关键指标:短期可反映市场情绪,高卖空比例预示看空预期,但极端值可能触发轧空反弹;长期结合基本面恶化则预警下行风险。需注意其局限性:卖空行为包含对冲需求,未必单纯看空;机构可能通过衍生品做空未体现在数据中,且散户跟风易扭曲信号。股市有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715172504a44c0033&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715172504a44c0033&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2488822045.USD","02268","SG9999014674.SGD","BK1141"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.youyuan.com.hk","stockEarnings":[{"period":"1week","weight":0.25},{"period":"1month","weight":0.5476},{"period":"3month","weight":0.6895},{"period":"6month","weight":1.2133},{"period":"1year","weight":3.2763},{"period":"ytd","weight":1.0147}],"compareEarnings":[{"period":"1week","weight":0.0157},{"period":"1month","weight":0.0511},{"period":"3month","weight":0.1539},{"period":"6month","weight":0.262},{"period":"1year","weight":0.4807},{"period":"ytd","weight":0.2724}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"药明合联生物技术有限公司是一家主要从事提供提供抗体偶联药物(ADC)及其他生物偶联药物的全面合同研究、开发及制造组织(CRDMO)服务的投资控股公司。该公司的服务包括生物偶联药物、单克隆抗体中间体及生物偶联药物相关连接子及有效载荷的发现、工艺开发及优良生产质量管理规范(GMP)生产。该公司透过按有偿服务(FFS)基准的合约和按全时当量(FTE)基准的合约向客户提供CRDMO服务。该公司主要在国内市场、北美、欧洲和世界其他地区市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.222222,"avgChangeRate":0.010265},{"month":2,"riseRate":0.666667,"avgChangeRate":0.058284},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.010372},{"month":4,"riseRate":0.555556,"avgChangeRate":0.03555},{"month":5,"riseRate":0.333333,"avgChangeRate":0.006014},{"month":6,"riseRate":0.4,"avgChangeRate":-0.032735},{"month":7,"riseRate":0.4,"avgChangeRate":0.011785},{"month":8,"riseRate":0.4,"avgChangeRate":-0.114063},{"month":9,"riseRate":0.333333,"avgChangeRate":0.019767},{"month":10,"riseRate":0.777778,"avgChangeRate":0.151657},{"month":11,"riseRate":0.333333,"avgChangeRate":0.008796},{"month":12,"riseRate":0.111111,"avgChangeRate":-0.068876}],"exchange":"SEHK","name":"药明合联","nameEN":"WUXI XDC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.4","shortVersion":"4.34.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"药明合联(02268)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供药明合联(02268)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"药明合联,02268,药明合联股票,药明合联股票老虎,药明合联股票老虎国际,药明合联行情,药明合联股票行情,药明合联股价,药明合联股市,药明合联股票价格,药明合联股票交易,药明合联股票购买,药明合联股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"药明合联(02268)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供药明合联(02268)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}